What is the appropriate apixaban (Eliquis) dosing for acute deep vein thrombosis in a female patient aged ≥80 years with low body weight and impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Apixaban Dosing for Acute DVT

For this patient with acute DVT, the appropriate apixaban (Eliquis) dose is 10 mg orally twice daily for the first 7 days, followed by 5 mg twice daily thereafter—the standard treatment regimen without dose reduction. 1

Rationale for Standard Dosing

This patient does not qualify for dose reduction despite meeting some criteria that might initially suggest otherwise. Here's the critical distinction:

Dose Reduction Criteria Apply ONLY to Atrial Fibrillation

The dose reduction criteria (age ≥80 years, weight ≤60 kg [approximately 132 lbs], serum creatinine ≥1.5 mg/dL) apply exclusively to stroke prevention in atrial fibrillation, not to VTE treatment 2, 1. This patient:

  • Is in her late 80s (meets age criterion)
  • Weighs 118 pounds/53.6 kg (meets weight criterion)
  • Has Cr 0.97 mg/dL (does NOT meet creatinine criterion)

However, these criteria are irrelevant for acute DVT treatment.

VTE Treatment Has No Pre-Specified Dose Reductions

For treatment of DVT/PE, apixaban has no pre-specified dose-reduction criteria based on age, weight, or renal function 3, 4. The FDA-approved regimen for acute VTE is uniform: 10 mg twice daily for 7 days, then 5 mg twice daily 1.

Renal Function Considerations

With a GFR of 53 mL/min (CKD Stage 3a), this patient has mild-to-moderate renal impairment. Importantly:

  • Apixaban is safe in moderate renal impairment for VTE treatment without dose adjustment 4, 5
  • Apixaban has the lowest renal clearance (approximately 25%) among DOACs, making it particularly suitable for patients with renal dysfunction 5
  • No dose adjustment is recommended until CrCl falls below 15 mL/min 6

Treatment Regimen

Initial Phase (Days 1-7):

  • Apixaban 10 mg orally twice daily 1, 4

Maintenance Phase (Day 8 onward):

  • Apixaban 5 mg orally twice daily 1, 4

Extended Therapy (after 6 months, if indicated):

  • May consider reducing to 2.5 mg twice daily for secondary prevention 7, 4

Common Pitfalls to Avoid

  1. Do not inappropriately apply atrial fibrillation dose-reduction criteria to VTE treatment - This is the most common dosing error in clinical practice 8. Studies show that up to 60% of patients receiving reduced-dose apixaban do not meet appropriate criteria, often due to confusion between AF and VTE dosing guidelines.

  2. Do not reduce dose based on age or weight alone in VTE - While this patient is elderly and underweight, these factors alone do not warrant dose reduction for acute DVT treatment 5, 1.

  3. Do not use parenteral lead-in therapy - Unlike dabigatran and edoxaban, apixaban does not require initial heparin or LMWH 3, 4, 5. Starting with parenteral anticoagulation would be unnecessary and increase bleeding risk.

Monitoring Considerations

While routine laboratory monitoring is not required, this elderly patient with borderline renal function warrants:

  • Periodic renal function assessment (every 3-6 months given CKD Stage 3a) 9, 6
  • Assessment for bleeding risk factors
  • Medication adherence evaluation

In rare circumstances requiring perioperative planning or suspected accumulation, apixaban-calibrated anti-Xa levels may be useful 10, though this is not routine practice.

References

Research

Apixaban anti-Xa levels in clinical practice: A case report.

British journal of clinical pharmacology, 2024

Related Questions

What is the appropriate dose of apixaban (Eliquis) for an 80-year-old woman weighing 53 kg with normal renal function and a CHA₂DS₂‑VASc score of 3 who has atrial flutter?
Can Eliquis (apixaban) be used to treat deep‑vein thrombosis (DVT) in adults, and what is the recommended dosing and contraindications?
What is the recommended duration of Eliquis (apixaban) therapy for a leg deep‑vein thrombosis (DVT)?
What is the appropriate dosing of apixaban (Eliquis) for atrial fibrillation, acute deep‑vein thrombosis/pulmonary embolism, and postoperative prophylaxis, and what are the contraindications and dose adjustments based on age, weight, and renal function?
In a female patient with recent femoral deep vein thrombosis who is on apixaban (apixaban) for coronary stents, is a blood pressure of 172 mm Hg systolic and 61 mm Hg diastolic during a treadmill stress test an abnormal hypertensive response?
Does high-dose intramuscular progesterone for IVF luteal support increase LDL cholesterol or hinder weight loss?
In a 39‑year‑old man on antihypertensive therapy who has a persistent headache despite taking his blood pressure medication and Excedrin (acetaminophen/aspirin/caffeine) without relief, and whose blood pressure is not markedly elevated, could this represent end‑organ damage?
What is pre‑habilitation (pre‑hab) and how should it be initiated immediately for a patient awaiting orthopedic surgery?
What treatments are appropriate for a healthy adult with a dry cough in the absence of infection?
How should I write an order for meropenem‑induced anaphylaxis?
What is the appropriate workup for acute deep vein thrombosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.